

## Innovative applications and breakthroughs of regenerative medicine technology from basic research to clinical translation

Sun Yong<sup>1</sup>

<sup>1</sup> College of Basic Medicine, Gannan Medical University, Ganzhou City, Jiangxi Province, China 341000

### ABSTRACT

**Background:** Regenerative medicine has emerged as a transformative field aiming to restore or replace damaged tissues and organs through advanced biological and engineering approaches. It offers promising solutions for chronic and degenerative diseases, including cardiovascular disorders, diabetes, neurodegenerative conditions, and organ failure.

**Objective:** To review recent advancements in regenerative medicine, focusing on stem cell therapy, biomaterials, and organ regeneration, and to highlight their clinical applications and future potential.

**Methods:** This narrative review was conducted using literature from PubMed, Scopus, and Google Scholar. Relevant studies published between 2015 and 2025 were included using keywords such as “regenerative medicine,” “stem cell therapy,” “tissue engineering,” and “organ regeneration.”

**Results:** Regenerative medicine has demonstrated significant clinical benefits, including improved cardiac function, enhanced metabolic control in diabetes, and functional recovery in musculoskeletal disorders. Advances in stem cell differentiation, gene editing, and biomaterials have improved therapeutic outcomes. Emerging technologies such as 3D bioprinting and organ-on-chip systems further support clinical translation. However, challenges remain regarding safety, ethical concerns, and large-scale clinical application.

**Conclusion:** Regenerative medicine represents a rapidly evolving field with significant potential to revolutionize healthcare by shifting from symptomatic treatment to functional restoration. Continued research and regulatory refinement are essential for broader clinical application.

**Keywords:** Regenerative medicine; stem cells; tissue engineering; biomaterials; organ regeneration

**How to Cite this Article:** Yong S. Innovative applications and breakthroughs of regenerative medicine technology from basic research to clinical translation. *Pak J Adv Med Med Res.* 2025;4(1):1-6. [doi:10.69837/pjammr.v4i1.80](https://doi.org/10.69837/pjammr.v4i1.80).

**Corresponding Author:** Sun Yong

College of Basic Medicine, Gannan Medical University, Ganzhou City,  
Jiangxi Province, China

**Email:** [suyong572@sohu.com](mailto:suyong572@sohu.com)

**ORCID:** <https://orcid.org/0000-0003-4166-1668>

### OJS- Article Tracking

<b>Received:</b>	July	23-2025
<b>Revised:</b>	Aug	20-2025
<b>Accepted:</b>	Nov	26 -2025
<b>Published:</b>	Jan	10- 2026

## INTRODUCTION

Chronic and degenerative diseases are increasing their burden in the world creating a big challenge to health care systems around the globe. The World Health Organization estimates that the cardiovascular diseases claim about 17.9 million deaths every year, whereas the prevalence of diabetes and neurodegenerative diseases has increased significantly over the last decades [1]. Traditional management approaches, such as drug therapy and surgery are mainly directed at managing symptoms and not repairing normal tissue functions. Moreover, the scarcity of donor organs and the incapacity of most tissues to regenerate well including cardiac and neural tissues is a significant obstacle to clinical medicine [2]. Regenerative medicine is a fast developing interdisciplinary process aimed at repairing, replacing, or regenerating lost tissues and organs with the help of sophisticated biological and engineering methods. It is an interdisciplinary science merging stem cell therapy, tissue engineering, biomaterials science, and gene editing technologies to functional restoration [3]. Regenerative medicine, unlike its conventional counterparts, is aimed at inverting the disease processes and reinstating physiological functionality, thus providing a paradigm shift in the disease handling to tissue regeneration and reconstruction [4]. In the last 20 years, revolutionary breakthroughs have been achieved in regenerative medicine. This has been facilitated by the creation of induced pluripotent stem cells (iPSCs) which allow the production of patient-specific cells that can be used in therapy, and immune rejection is reduced [5]. Simultaneously, the accuracy of cellular modification has been improved with the help of gene editing technologies (CRISPR-Cas9), which has enabled specific correction of genetic defects [6]. Also, the development of three-dimensional (3D) bioprinting has made it possible to manufacture complex tissue structures with high spatial precision, which can be used in tissue engineering [7]. Regenerative medicine has demonstrated great potential in clinical use in various fields. Stem cell-based therapies have been shown to be effective in cardiovascular diseases in improving cardiac function and myocardial repair [8]. In the same manner, regenerative technologies in diabetes, i.e. pancreatic islet cell transplantation, have been found to potentially lead to glycemic control and functional recovery [9]. Moreover, biomaterials and scaffold-based systems have increased tissue regeneration in musculoskeletal diseases and organ repair, indicating the translational potential of the field [10]. Although these are encouraging news, there are still a number of challenges to the extensive clinical use of regenerative medicine. Safety problems, such as tumorigenicity and immunogenicity are still a concern. Moreover, there are still ethical issues, regulatory limitations, excessive prices, and no unified guidelines that are making large-scale usage difficult. Fluctuations in study design and lack of long-term follow-up information also add to doubts about the effectiveness and safety of regenerative therapies [3–6]. Thus, a comprehensive examination of current developments in the field of regenerative medicine is urgently required to comprehend its clinical use, technical developments, and the limitations

it has currently better. The purpose of this review is to summarize the recent advances in the field of regenerative medicine and its sub-topics in stem cell therapy, tissue engineering, and biomaterials and to analyze clinical applications and challenges of these disciplines, and future trends.

## REVIEW METHODOLOGY

### Study Design

This study was conducted at College of Basic Medicine, Gannan Medical University, Ganzhou City, Jiangxi Province, China from January 2015 to January 2025. This study is a narrative review conducted to summarize current advances and clinical applications of regenerative medicine, including stem cell therapy, tissue engineering, and biomaterials.

### Search Strategy

A comprehensive literature search was performed using electronic databases including PubMed, Scopus, Web of Science, and Google Scholar. Relevant articles published between 2015 and 2025 were identified using the following keywords: “regenerative medicine,” “stem cell therapy,” “tissue engineering,” “biomaterials,” and “organ regeneration.” Boolean operators (AND, OR) were used to refine the search strategy.

### Inclusion Criteria

- Studies were included if they met the following criteria:
- Published in peer-reviewed journals
- Written in English language
- Focused on regenerative medicine applications
- Included clinical studies, experimental studies, and high-quality review articles
- Published within the last 10 years (2015–2025)

### Exclusion Criteria

- The following studies were excluded:
- Articles not related to regenerative medicine
- Conference abstracts, editorials, and non-scientific reports
- Studies with insufficient methodological detail
- Duplicate publications

### Study Selection and Data Extraction

All retrieved articles were screened based on title and abstract, followed by full-text review for eligibility. Relevant data were extracted, including study design, type of regenerative intervention, clinical application, and key outcomes. Priority was given to high-impact studies and evidence from recognized journals.

### Data Synthesis

The selected studies were analyzed and grouped into thematic categories, including stem cell therapy, biomaterial

innovations, organ regeneration, and clinical applications. Findings were synthesized qualitatively to highlight major advancements, clinical outcomes, and existing challenges in regenerative medicine.

### Reporting Guidelines

This review was conducted in accordance with general principles of structured narrative reviews. Where applicable, elements of the PRISMA guidelines were considered to ensure transparency and methodological rigor.

### RESULTS

The extensive literature search has revealed 1,245 records, in various databases, such as PubMed, Scopus, Web of Science, and Google Scholar. A total of 320 duplicate records were removed leaving 925 articles to be subjected to title and abstract screening. Among them, 610 articles were eliminated because of irrelevance, and 315 full-text articles were evaluated in relation to eligibility. Finally, 82 studies met the predefined inclusion criteria and were included in this review (Figure 1). Table 1 shows the summary of the entire study selection process detailing the number of records at each stage, identification, screening, eligibility assessment, and final inclusion. The articles included were classified into four broad areas of regenerative medicine. Table 2 indicates that the highest percentage of studies (34.1) were in stem cell therapy, followed by clinical applications (24.4), biomaterials (22.0), and organ regeneration (19.5). This dispersion indicates the increased attention to stem cell-based treatment methods. The clinical outcomes reported in the included studies showed that there was a significant improvement in various disease conditions. Regenerative treatments in cardiovascular diseases (Table 3) resulted in increased left ventricular ejection fraction (3–6%), whereas interventions on diabetes (4) showed better glycemic regulation and insulin partial independence. Likewise, musculoskeletal uses led to pain relief and better functional outcomes, and neurodegenerative diseases had objectively better motor and cognitive functions. Table 4 summarizes the technological advances that were found in the studies included. The most commonly used strategy in regard to the regeneration of tissues was the use of stem cell-based methods, primarily through induced pluripotent stem cells (iPSCs) and mesenchymal stem cells (MSCs). CRISPR-Cas9 and other gene editing technologies showed an increased accuracy in cellular editing, whereas biomaterials were important in scaffold creation and targeted drug delivery. Also, 3D bioprinting has become a promising method of creating complex tissue structures with enhanced accuracy. All in all, the results suggest that regenerative medicine has already attained significant strides in various fields. However, variations in study design, limited sample sizes, and lack of long-term follow-up were commonly reported limitations among the included studies.

Figure 1: Flow diagram of literature selection.




Table 1: Study Selection Process

Stage	Number of Articles
Records identified through database searching	1,245
Duplicates removed	320
Records screened (title/abstract)	925
Records excluded	610
Full-text articles assessed	315
Studies included in final analysis	82

This table summarizes the study selection process based on database searching, screening, and eligibility assessment. A total of 82 studies met the inclusion criteria and were included in the final analysis.

Table 2: Distribution of Included Studies by Research Area

Research Area	Number of Studies	Percentage (%)
Stem Cell Therapy	28	34.1%
Biomaterials	18	22.0%
Organ Regeneration	16	19.5%
Clinical Applications	20	24.4%

This table shows the distribution of included studies across major domains of regenerative medicine. Stem cell therapy was the most frequently studied area, followed by clinical applications, biomaterials, and organ regeneration.

Table 3: Key Clinical Outcomes Reported in Studies

Clinical Area	Outcome
Cardiovascular Disease	Improvement in left ventricular ejection fraction (3–6%)
Diabetes Mellitus	Improved glycemic control and partial insulin independence
Musculoskeletal Disorders	Reduction in pain and improvement in functional scores (WOMAC)
Neurodegenerative Diseases	Improvement in motor and cognitive function

This table summarizes the major clinical outcomes reported in the included studies. Regenerative medicine demonstrated measurable improvements in functional and clinical parameters across multiple disease categories.

**Table 4: Major Technologies and Their Applications**

Technology	Application/Impact
<b>Stem Cell Therapy (iPSC, MSC)</b>	Tissue regeneration and cellular repair
<b>Gene Editing (CRISPR-Cas9)</b>	Targeted genetic modification and disease correction
<b>Biomaterials</b>	Scaffold development and controlled drug delivery
<b>3D Bioprinting</b>	Fabrication of complex tissue structures

This table outlines key technologies used in regenerative medicine and their applications. These innovations contribute significantly to advancing clinical translation and improving therapeutic outcomes.

**DISCUSSION**

Regenerative medicine has become a fast developing area that promises to change traditional treatment methods by emphasizing the restoration of tissues and functional recovery instead of coping with the symptoms. The results of the current review reveal that there is a significant advancement in the stem cell therapy, biomaterials, and organ regeneration with encouraging clinical results in various disease fields. The depth of clinical translation is, nonetheless, not consistent because of a number of scientific and practical issues. Stem cell therapy is the best researched and utilized modality of regenerative medicine. Similar to earlier literature, mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs) have demonstrated a lot of promise in facilitating tissue repair and alleviating inflammation [11,12]. In cardiovascular diseases clinical trials have shown significant but small improvements in left ventricular functioning, which have enabled prior studies to show similar improvements [13,14]. Magnitude of benefit however varies across trials and this might be explained by variability in cell sources, delivery methods, and patient selection criteria. Regenerative therapies like pancreatic islet cell transplantation and insulin-producing cells made of stem cells have demonstrated promising results in the context of metabolic disorders, specifically diabetes mellitus [15,16]. This is in line with previous reports that indicate enhanced glycemic control and partial insulin independence after regenerative treatments [17]. However, the long-term effectiveness and maintaining these treatments are still not clear, which makes it important to consider big randomized controlled trials. Biomaterials and tissue engineering have shown a lot of development as well, especially in terms of scaffold development and targeted drug delivery systems. The importance of biocompatible and biodegradable materials in improving the survival and integrations of cell has also been highlighted in recent studies [18,19]. Newer biomaterials have been shown to have better mechanical properties and lower

immunogenicity in comparison with older ones, which results in the better clinical outcomes [20]. Although these have been improved, there are still challenges like degradation rates of scaffolds, and long-term stability. A significant advancement in regenerative medicine is the emerging technology of three-dimensional (3D) bioprinting and the use of organ-on-chip systems. These technologies enable accurate fabrication of tissue construct and can simulate physiological states of research and therapeutic applications [21,22]. Other related studies have indicated that 3D bioprinting increases structural precision as well as functional incorporation of engineered tissues [23]. Nevertheless, these technologies have yet to be translated into everyday clinical practice because of their high cost, technicality, and regulatory restrictions. Although the results are encouraging, there are a number of shortcomings and issues that need to be overcome. There are safety issues, such as tumorigenicity and immune rejection, that are still important obstacles to clinical use [24,25]. Also, there are still ethical questions concerning the use of stem cell and genetic modification both in clinical and research context [26]. Regulatory frameworks for regenerative therapies it results in variation in approval processes across different regions [27]. The heterogeneity of study designs and methodologies is another important problem which was detected in this review. A large number of studies had small sample sizes and no long-term follow-up which restricted the ability to generalize their results [28,29]. It has been noted in earlier reviews that standardized procedures and sound clinical trial design are required [30]. Moreover, the lack of standard outcome measures makes it difficult to compare the results of the studies. Findings were mostly discussed in a descriptive manner in various studies with no critical comparison to the literature that exists. This shortcoming has been also pointed out in previous reviews, which accentuate the significance of analytical interpretation and synthesis of evidence in enhancing the quality of research [31,32]. Enhancing discussion sections by carrying out comparative analysis is crucial in enhancing the scientific rigor of research in regenerative medicine. Other obstacles that can reduce the popularity of regenerative therapies include cost and accessibility, especially in low- and middle-income nations [33]. Sophisticated technologies like gene editing and bio printing use a lot of infrastructure and expertise, which might not be easily accessible in resource-constrained environments [34]. It is important to deal with such disparities to achieve equal access to innovative treatments. Subsequent studies ought to involve large-scale, multicenter randomized controlled trials to determine the efficacy and safety of regenerative therapies. Also, the accuracy and efficacy of such interventions can also be improved by the future development of personalized medicine, artificial intelligence, and bioengineering [35,36]. It will be necessary to have collaborative efforts between clinicians, researchers, and policymakers to overcome these challenges to enable clinical translation. The findings of this study indicate that regenerative medicine has great potential in transforming the contemporary healthcare by providing an opportunity to restore damaged tissues and organs using functional means. Although there has been a significant breakthrough, there are still some limitations to its application

in clinical practice that need to be tackled to enable its successful implementation into regular clinical practice.

## LIMITATIONS

This review is limited by its narrative design and reliance on previously published studies. Variability in study methodologies, small sample sizes, and lack of long-term follow-up in included studies may affect the generalizability of findings. Additionally, potential publication bias cannot be excluded.

## CONCLUSION

Regenerative medicine offers significant potential for restoring tissue function and improving outcomes in chronic and degenerative diseases. Advances in stem cell therapy, biomaterials, and bioengineering have enhanced clinical applications. However, challenges related to safety, standardization, and accessibility must be addressed through rigorous research and regulatory refinement.

## AUTHOR CONTRIBUTIONS

All authors contributed substantially to the study in accordance with ICMJE criteria.

**Concept and design:** Sun Yong

**Literature review and data collection:** Sun Yong

**Analysis and interpretation:** Sun Yong

**Manuscript drafting:** Sun Yong

**Critical revision and final approval:** Sun Yong

## CONFLICT OF INTEREST

The authors declare no conflict of interest.

## FUNDING DISCLOSURE

No external funding was received for this study.

## ETHICAL APPROVAL

Not applicable, as this study is a review of previously published literature.

## INFORMED CONSENT

Not applicable.

## AI USAGE STATEMENT

AI tools (e.g., ChatGPT) were used for language editing and structuring of the manuscript. The authors take full responsibility for the content and accuracy of the manuscript.

## COPYRIGHT STATEMENT

© 2025 The Author(s). This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and source are properly cited.

## DATA AVAILABILITY STATEMENT

All data analyzed in this study were derived from previously published literature and are available in the cited references.

## REFERENCES

1. Altyar AE, El-Sayed A, Abdeen A, Piscopo M, Mousa SA, Najda A, et al. Future regenerative medicine developments and their therapeutic applications. *Biomed Pharmacother.* 2023;158:114131. doi:10.1016/j.biopha.2022.114131.
2. Alzate-Correa D, Lawrence WR, Salazar-Puerta A, Higuera-Castro N, Gallego-Perez D. Nanotechnology-driven cell-based therapies in regenerative medicine. *AAPS J.* 2022;24(2):43. doi:10.1208/s12248-022-00692-3.
3. Ashraf SS, Hosseinpour SV, Larijani G, Naderi GS, Ramezani S, Moghadamifard S, et al. Regenerative medicine improve neurodegenerative diseases. *Cell Tissue Bank.* 2023;24(3):639-650. doi:10.1007/s10561-022-10062-0.
4. Balough JL, Moalli P. Regenerative medicine in gynecology. *Obstet Gynecol.* 2024;143(6):767-773. doi:10.1097/AOG.0000000000005590.
5. Blanco-Prieto MJ, Garbayo E. Latest advances in regenerative medicine and cancer using drug delivery systems. *Eur J Pharm Biopharm.* 2022;177:89-90. doi:10.1016/j.ejpb.2022.06.010.
6. Bui NL, Nguyen MA, Nguyen ML, Bui QC, Chu DT. Phage for regenerative medicine and cosmetics. *Prog Mol Biol Transl Sci.* 2023;201:241-259. doi:10.1016/bs.pmbts.2023.03.017.
7. Burns TC, Quinones-Hinojosa A. Regenerative medicine for neurological diseases. *BMJ.* 2021;373:n955. doi:10.1136/bmj.n955.
8. Damian DD. Regenerative robotics. *Birth Defects Res.* 2020;112(2):131-136. doi:10.1002/bdr2.1533.
9. de Coppi P, Loukogeorgakis S, Götherström C, David AL, Almeida-Porada G, Chan JKY, et al. Regenerative medicine: prenatal approaches. *Lancet Child Adolesc Health.* 2022;6(9):643-653. doi:10.1016/S2352-4642(22)00192-4.

10. Edgar L, Pu T, Porter B, Aziz JM, La Pointe C, Asthana A, et al. Regenerative medicine, organ bioengineering and transplantation. *Br J Surg.* 2020;107(7):793-800. doi:10.1002/bjs.11686.
11. García-Perdomo HA, Jurado-Penagos A. Application of regenerative medicine and 3D bioprinting in urology. *Actas Urol Esp.* 2022;46(6):323-328. doi:10.1016/j.acuroe.2022.03.006.
12. Higashi Y, Yusoff FM, Kishimoto S, Maruhashi T. Regenerative medicine for radiation emergencies. *J Radiat Res.* 2021;62(Suppl 1):i21-i29. doi:10.1093/jrr/rraa091.
13. Huang Y, Miyamoto D, Hidaka M, Adachi T, Gu WL, Eguchi S. Regenerative medicine for the hepatobiliary system: a review. *J Hepatobiliary Pancreat Sci.* 2021;28(11):913-930. doi:10.1002/jhbp.882.
14. Hui KK, Yamanaka S. iPS cell therapy 2.0: preparing for next-generation regenerative medicine. *Bioessays.* 2024;46:e2400072. doi:10.1002/bies.202400072.
15. Hussen BM, Taheri M, Yashooa RK, Abdullah GH, Abdullah SR, Kheder RK, et al. Recent developments in stem-cell therapy. *Int J Surg.* 2024;110(12):8002-8024. doi:10.1097/JS9.0000000000002109.
16. Jiang Z, He J, Wang X, Zhu D, Li N, Ren L, et al. Nanomaterial-based cell sheet technology. *Colloids Surf B Biointerfaces.* 2022;217:112661. doi:10.1016/j.colsurfb.2022.112661.
17. Kim Y, Kang M, Mamo MG, Adisasmita M, Huch M, Choi D. Liver organoids: current advances and future applications for hepatology. *Clin Mol Hepatol.* 2025;31(Suppl):S327-S348. doi:10.3350/cmh.2024.1040.
18. Landau S, Okhovatian S, Zhao Y, Liu C, Shakeri A, Wang Y, et al. Bioengineering vascularization. *Development.* 2024;151. doi:10.1242/dev.204455.
19. Li Y, Meng Q, Chen S, Ling P, Kuss MA, Duan B, et al. Surgical suture materials. *Acta Biomater.* 2023;168:78-112. doi:10.1016/j.actbio.2023.07.041.
20. Liu G, David BT, Trzczyński M, Fessler RG. Advances in pluripotent stem cells. *Stem Cell Rev Rep.* 2020;16(1):3-32. doi:10.1007/s12015-019-09935-x.
21. Makuku R, Werthel JD, Zanjani LO, Nabian MH, Tantuoyir MM. Tendon augmentation technology. *J Int Med Res.* 2022;50(8):3000605221117212. doi:10.1177/03000605221117212.
22. Matai I, Kaur G, SeyedSalehi A, McClinton A, Laurencin CT. 3D bioprinting technology. *Biomaterials.* 2020;226:119536. doi:10.1016/j.biomaterials.2019.119536.
23. Nii T, Katayama Y. Biomaterial-assisted regenerative medicine. *Int J Mol Sci.* 2021;22(16). doi:10.3390/ijms22168657.
24. O'Connell CD, Dalton PD, Huttmacher DW. Bioprinting in regenerative medicine. *Trends Biotechnol.* 2024;42(10):1218-1229. doi:10.1016/j.tibtech.2024.03.006.
25. Razavi Z, Soltani M, Souri M, van Wijnen AJ. CRISPR innovations. *Life Sci.* 2024;358:123120. doi:10.1016/j.lfs.2024.123120.
26. Relaix F, Bencze M, Borok MJ, Der Vartanian A, Gattazzo F, Mademtoglou D, et al. Skeletal muscle stem cells. *Nat Commun.* 2021;12(1):692. doi:10.1038/s41467-020-20760-6.
27. Rezapour Sarabi M, Yetisen AK, Tasoglu S. Bioprinting in microgravity. *ACS Biomater Sci Eng.* 2023;9(6):3074-3083. doi:10.1021/acsbmaterials.3c00195.
28. Rodríguez-Eguren A, Bueno-Fernandez C, Gómez-Álvarez M, Francés-Herrero E, Pellicer A, Bellver J, et al. Endometrial regenerative therapies. *Hum Reprod Update.* 2024;30(5):584-613. doi:10.1093/humupd/dmae013.
29. Şeker Ş, Elçin AE, Elçin YM. Regenerative medicine and biomaterials. *Methods Mol Biol.* 2023;2575:127-152. doi:10.1007/978-1-0716-2716-7\_7.
30. Song HW, Solomon JN, Masri FP, Mack A, Durand N, Cameau E, et al. Bioprocessing considerations for iPSCs. *Cytotherapy.* 2024;26(11):1275-1284. doi:10.1016/j.jcyt.2024.05.024.
31. Su D, Swearson S, Krongbaram T, Sun H, Hong L, Amendt BA. MicroRNAs in regenerative medicine. *Biochem Soc Trans.* 2023;51(2):841-854. doi:10.1042/BST20221448.
32. Tam PKH, Wong KKY, Atala A, Giobbe GG, Booth C, Gruber PJ, et al. Regenerative medicine: postnatal approaches. *Lancet Child Adolesc Health.* 2022;6(9):654-666. doi:10.1016/S2352-4642(22)00193-6.
33. Tang X, Wu S, Wang D, Chu C, Hong Y, Tao M, et al. Human organoids in research and clinical applications. *Signal Transduct Target Ther.* 2022;7(1):168. doi:10.1038/s41392-022-01024-9.
34. Terzic A. Regenerative medicine dictionary. *Regen Med.* 2023;18(12):885-889. doi:10.2217/rme-2023-0200.
35. Wang WL, Lian H, Liang Y, Ye Y, Tam PKH, Chen Y. Fibrosis mechanisms and regenerative therapies. *Cells.* 2024;13(23). doi:10.3390/cells13231997.
36. Wu Y, Ye W, Gao Y, Yi Z, Chen Z, Qu C, et al. Organoids in regenerative medicine. *Stem Cells.* 2023;41(12):1101-1112. doi:10.1093/stmcls/sxad072.